---
title: A real-world experience of venetoclax combined with hypomethylating agents
  vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes
  and chronic myelomonocytic leukemia patients
date: '2024-05-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38756378/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1T5FW5K6kI7Ui-YFfm6b8NuT1rAqMfZcYcvuOELhU7ZdLYMMmI&fc=20220727230845&ff=20240517180438&v=2.18.0.post9+e462414
source: (yan,xiaojing[Author]) AND (China medical university[Affiliation])
description: 'INTRODUCTION: Current clinical research has reported the effectiveness
  and safety of venetoclax in combination with hypomethylating agents (VEN-HMA) in
  patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia
  (CMML). Thus, this study aimed to examine the effectiveness and safety of VEN-HMA
  therapy in patients with MDS and CMML and compared its short-term and long-term
  therapeutic effects with HMA ...'
disable_comments: true
---
INTRODUCTION: Current clinical research has reported the effectiveness and safety of venetoclax in combination with hypomethylating agents (VEN-HMA) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Thus, this study aimed to examine the effectiveness and safety of VEN-HMA therapy in patients with MDS and CMML and compared its short-term and long-term therapeutic effects with HMA ...